HYDERABAD, INDIA (Apr 05, 2011) – Suven Life Sciences Limited an ISO 9001, ISO 14001 and OHSAS 18001 company has undergone US FDA renewal inspection at their facility in Pashamylaram, near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs) and intermediates under cGMP.
Based on the inspection and the review thereafter US-FDA has classified Suven facility at Pashamylaram as acceptable for manufacture and supply of active pharmaceutical ingredients and intermediates.
So far Suven Life Sciences has filed 16 DMF’s and one ANDA from this facility which is now FDA complaint under cGMP. With partner ANDA approvals Suven can supply the active pharmaceutical ingredients in future thus generating new revenues in due course of time.
Suven Life Sciences is a Hyderabad based Life Science company is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery and Development Support Services (DDDSS) since 2005, a Collaborative Research Partner (CRP) in Drug Discovery for a global Pharma major since 2006 and has in house program for discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer’s disease and Schizophrenia
For more information on Suven please visit our Web site at http://www.suven.com
